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CANNABIDIOL INDUCES APOPTOSIS AND PERTURBS MITOCHONDRIAL 




Cannabidiol (CBD), the major non-psychoactive compound found in cannabis, is 
frequently used both as a nutraceutical and therapeutic. Clinical studies suggest CBD 
may be beneficial for treating rare forms of epilepsy and inflammatory conditions but 
despite anecdotal evidence as an anticancer agent, little is known about the effect it has 
on cancer cells. Given the intractability and poor prognoses of brain cancers in both 
human and veterinary medicine, we characterized the in vitro cytotoxicity of CBD on 
human and canine gliomas. Glioma cells treated with CBD showed a range of 
cytotoxicity from 4.9-8.2 g/mL; canine cells appeared to be more sensitive than human. 
Treatment with >5 g/mL CBD invariably produced large cytosolic vesicles. Next, the 
mode of cell death was interrogated using pharmacologic inhibitors. Inhibition of 
apoptosis was sufficient to rescue CBD-mediated cytotoxicity. Inhibition of RIPK3, a 
classical necroptosis protein, rescued cells from death and prevented the formation of 
the large cytosolic vesicles. Analysis of cell death by resazurin reduction showed much 
higher sensitivity than other cytotoxicity methods and suggested disruption of the 
mitochondria. Cellular mitochondrial activity in the presence of CBD was assessed and 
within two hours of treatment CBD reduced oxygen consumption in a dose dependent 
manner with almost complete ablation of activity at 10 g/mL CBD. Fluorescent imaging 
with a mitochondrial-specific dye revealed that the large cytosolic vesicles were, in fact, 
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swollen mitochondria. Lastly, calcium channels were inhibited and the effect on cell 
death was measured. Inhibition of mitochondrial channel VDAC1, but not the TRPV1 
channel, rescued cells from CBD-mediated cytotoxicity. These results demonstrate the 
cytotoxic nature of CBD in human and canine glioma cells and suggest a mechanism of 
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The prognosis following a glioma diagnosis is notoriously grave, no matter the 
species. High grade gliomas portend a median survival rate of 14–16 months in human1 
and 2–4 months in canine patients.2 Tumor cell resistance to the currently available 
multimodal treatments underlies these dismal prognoses. Unfortunately, improvements 
in patient outcome have not paralleled the medical advances in glioma treatment 
regimens.3,4 This highlights the crucial need for further brain cancer treatment research.  
Recently, the cannabinoid family, a group of pharmacologically active compounds 
that primarily interact with specific cannabinoid G-protein coupled receptors (GPCR)5, are 
being rigorously studied for their putative anti-tumorigenic and therapeutically relevant 
properties. These effects have been observed among a diverse family of cannabinoid 
compounds, such as naturally occurring cannabinoids, synthetic cannabinoid agonists, 
and endocannabinoid modulators.5 In particular, cannabidiol (CBD), a non-psychoactive 
phytocannabinoid derived from Cannabis sativa, has seen accumulating evidence it may 
function as an antineoplastic agent. CBD has been demonstrated to possess anti-
proliferative, cytotoxic, anti-migratory, anti-adhesive, anti-invasive, and anti-
neovascularization effects in a wide variety of histogenetically diverse cancer types in 
vitro.6,7,8 The observed cytotoxicity is hypothesized to result from activation of apoptotic 
and autophagic pathways, with a particular interest in the involvement of the Voltage 
Dependent Anion Channel 1 (VDAC1) ion channel.8, 29 The exact mechanism(s), 
however, of these antineoplastic effects remain nebulous.  
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  Current use of cannabinoids in cancer therapy is predominantly through non-
prescription cannabis, including tetrahydrocannabinol (THC) or related cannabinoid 
agonists for alleviation of unwanted concomitant effects of chemo- and radiotherapeutic 
regimens. While THC and similar cannabinoids are effective in palliative uses, patients 
often experience unwanted psychoactive effects and tolerance to and potentially 
dependence upon these treatments. CBD, in addition to being non-psychotropic, exhibits 
several therapeutically beneficial effects such as analgesia, anxiolysis, and anti-
inflammatory properties.9 
Cannabinoids exert their pharmacological effects through a wide variety of 
receptor-dependent and independent interactions. These interactions are capable of 
modifying signaling pathways that are crucial in tumorigenesis, cancer growth, and 
metastasis.10 The cannabinoid-specific GPCRs CB1 and CB2 make up the predominant 
population of the endocannabinoid system.11 CB1 is one the most common GPCR in the 
human and canine brain.11,12 CBD has little binding affinity to the cannabinoid receptors, 
but is capable of  modifying them and exerting effects through a diverse cornucopia of 
other receptors including, but not limited to: TRPV1, mTOR, PPAR, GABA and 5HT 
receptors.13,14,15,16 The TRPV1 receptor has been implicated in many of CBD’s clinical 
effects such as analgesia.16 The variable and ubiquitous nature of the cannabinoid 
signaling system in the brain results in diverse modification of crucial cellular pathways 
and suggests a potential for utilizing CBD as a targetable pharmacophore. Further 
detailing of these interactions will provide invaluable information about CBD’s effects on 
cells and reveal further potential of CBD as a therapeutic. 
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Several studies have demonstrated the remarkable similarities between canine and 
human gliomas, including MRI characteristics, histological and immunohistochemical 
features, genetic conservation, and immunological responses.17,18,19 Thus, 
spontaneously occurring canine gliomas serve as an ideal surrogate for human brain 
tumors. The present study explores the anti-cancer phenomena of CBD in human and 
canine glioma cells in vitro and details the biochemical mechanisms responsible as a 





































Cell culture and reagents 
Two canine glioma cells lines (J3TBG, SDT3G) were provided by UC Davis. 
J3TBG was derived from a grade III astrocytoma and SDT3G from a grade III 
glioblastoma sample.45 The human cell line U87MG was purchased from the University 
of Colorado Anschutz Tissue Culture Shared Resource (PMTSR). The human cell line 
U373MG Uppsala was purchased from the ECACC. All cell lines were cultured in 
Minimum Essential Media Eagle (MEM; Corning, Inc. Corning, NY) supplemented with 
10% FBS, 100 U/mL streptomycin, 4.5 g/L glucose and 10 mM sodium pyruvate at 
37oC, in 5% CO2. Cell cultures were maintained in semi-confluent monolayers and 
passaged 1-2 times per week. Cell lines were maintained for no more than 30 
passages, at which time a new stock was utilized. All cell lines were verified by STR 
(Short Tandem Repeats) at the Flint Animal Cancer Center Cell Line Validation Core at 
Colorado State University. Cells were verified to be mycoplasma-free via PCR prior to 
transduction with the IncuCyte™ NucLight Red lentiviral system (Essen Bioscience Inc., 
Ann Arbor, MI) and were selected with puromycin following transduction. CBD was 
provided by Extract Labs (Boulder, CO) and analyzed for purity. Two forms of CBD-
dominant products were provided: highly-purified CBD isolate (>99.9% pure 
cannabidiol) and CBD extract (96% CBD, 4% cannabinoid diverse). Both forms of CBD 
were prepared as a stock solution in DMSO, and later diluted to 100x working stocks in 
50/50 ethanol/ultra-pure water. z-VAD-fmk (final concentration of 50 µM,20 dissolved in 
50/50 ethanol/ultra-pure water), necrostatin-1 (final concentration of 100 µM,21 dissolved 
 5 
in DMSO/ultra-pure water), and VX-765 (final concentration of 50 µM,22 dissolved in 
50/50 ethanol/ultra-pure water) were purchased from Sigma-Aldrich (MilliporeSigma; 
Burlington, MA). GSK‘872 (final concentration of 1 µM,23 dissolved in 50/50 
ethanol/ultra-pure water),  4,4’-Diisothiocyano-2,2’-stilbenedisulfonic acid (DIDS) (final 
concentration of 50 µM,24 dissolved in 50/50 ethanol/ultra-pure water), and 5-IRTX (final 
concentration of 1 µM, 25 dissolved in 50/50 ethanol/ultra-pure water) were purchased 
from Tocris Bioscience (Bristol, United Kingdom). Concentrations of reagents were 
determined using previously published inhibitory values.  
Cytotoxicity Assays 
Cells were seeded in 96-well Nunclon Delta Surface Plate (Thermo-Scientific, 
Rockford, IL) at densities to ensure mid-late log phase growth at 96 hours (3000 
cells/well). Cells were allowed to adhere for a minimum of 4 hours before dosing. Cell 
viability was quantified utilizing the membrane impermeable dye YOYO-1 (Thermo-
Scientific, Rockford, IL) at 100 nM. Assays were imaged every 3 hours using IncuCyteTM 
Zoom (Essen Bioscience, Ann Arbor, MI). At 96 hours, the percentage of dead cells was 
calculated by dividing the measured final green fluorescence (a surrogate of cell death) 
by the sum of the final red fluorescence per mm2 (a surrogate of cell viability) and green 
fluorescence per mm2. Bars represent the mean across biological replicates, and the 
error bars represent the Standard Error Mean between biological replicates. 
Seahorse XFe24 Assays 
Cells were resuspended in Seahorse XF DMEM (Agilent Technologies, Santa 
Clara, CA) supplemented with 100 µg/mL streptomycin, 4.5 g/L glucose, and 10 mM 
sodium pyruvate. Cells were plated at an empirically determined density of 7.5 x 104 
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cells/well in Cell-Tak (Corning, Inc. Corning, NY) treated XF24 cell culture microplates 
(V7-PS; Seahorse Bioscience, North Billerica, MA). Cells were then spun at 500*g for 5 
minutes and allowed to equilibrate in a 37oC non-CO2 incubator immediately before 
metabolic flux analysis. Oxygen Consumption Rate/Extracellular Acidification Rate 
(OCR/ECAR) were then measured by the Agilent Seahorse XFe24 Analyzer (Agilent 
Technologies, Santa Clara, CA) under basal conditions for 30 minutes and post-
injection of compounds. The data were then validated by injection of oligomycin (18.5 
µM), rotenone/antimycin A (6.6 µM), and carbonyl cyanide m-chlorophenyl hydrazine (6 
µM). Graphs shown are single assays performed in technical triplicates and are 
representative replicates of observed trends across assays.  
Live Cell Imaging and Mitochondria Staining 
NucLight-Red transfected cells (SDT3G and U373MG) were plated onto Cellvis 
8-well chambered cover glass (C8-1.5H-N, Cellvis, Mountain View CA) in DMEM at a 
density to ensure 50-70% confluency at the time of dosing for live cell imaging studies. 
Cells were dosed with CBD after adhering to the cover glass. Incubation times as 
indicated were staggered such that all incubations would end at the time of imaging. 
Cells were stained with both MitoTracker Deep Red FM (M22426, ThermoFisher, 
Waltham MA) and Hoescht (33342, ThermoFisher, Waltham MA) prior to imaging. 
During the staining and imaging, cells were maintained in phenol red-free supplemented 
DMEM, termed “imaging media”, containing the following: penicillin/streptomycin 
(15140163, Gibco), L-glutamine (A2916801, Gibco), essential (11130-051, Gibco) and 
nonessential (11140-076, Gibco) amino acids all diluted to a final of 1x from the stock, 
and sodium bicarbonate (S233-500, Fisher, Waltham MA) at a final concentration of 
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1.5%. Before the end of the incubation, cells were washed once with imaging media and 
were stained with 50 nM MitoTracker diluted in imaging media for 15 minutes at 37C 
followed by 10 M Hoescht for 5 minutes at room temperature. CBD was maintained at 
appropriate concentrations for the staining and imaging steps. Live cell images were 
then visualized using an Olympus IX83 (Olympus, Tokyo, Japan) confocal microscope 
and Hamamatsu ORCA-R2 (Hamamatsu Photonics, Shizuoka, Japan) digital camera. 
Visual information corresponding to nuclear RFP (NucLight-Red) were captured for 
analysis but were excluded from the publication images. 
ATP Luminescence Assay 
Cellular ATP levels were measured using a luminescent ATP detection assay kit 
according to the manufacturer’s instruction (ab113849, Abcam, Cambridge, MA).  Cells 
were seeded at a density of 3000 cells/well, allowed to adhere for 4 hours, and dosed in 
the same method as the cytotoxicity assays. Luminescence of luciferase was read via a 
BioTek Synergy HTX 96-well microplate reader (Biotek, Winooski, VT). ATP 
concentration for individual wells was interpolated via standard curve in GraphPad 
Prism (GraphPad Software, Santa Clara, CA). Luminescence of cell culture media was 
subtracted from each well. Data was then averaged, corrected for proliferation, and 
subsequently normalized to their respective controls. Two biological replicates were 
performed. Graphs shown are single assays performed in technical triplicates and are 
representative replicates of observed trends across assays.  
Resazurin Metabolic Assay 
Resazurin sodium salt was purchased from Sigma-Aldrich (MilliporeSigma; 
Burlington, MA). Cells were seeded at a density of 3000 cells/well, allowed to adhere for 
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4 hours, and were subsequently dosed with varying conditions (0 – 20 µg) for a final 
well volume of 180 µL. Wells were dosed with same methods as cytotoxicity assays. 
After 96 hours, 20 µL of resazurin reagent was added to each well for a final well 
volume of 200 µL. Cells were then incubated for 4 hours in standard culture conditions. 
Resazurin reagent reduction, a surrogate of cell metabolism, was measured via 
fluorescence (excitation: 540 nm; emission: 590 nm) in a 96-well microplate reader. 
DMEM control fluorescence was subtracted for each well. Fluorescence data was 
averaged and subsequently normalized to their respective controls. Assays were 
performed in biological and technical triplicate: the bars represent the mean across 
biological replicates and the error bars represent the SEM between biological replicates.  
Data Analysis 
Unless specified, each assay condition was performed in technical triplicate and 
each assay was independently repeated at least 3 times. Statistical analysis was carried 
out using GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA). Statistical 





















CBD is anti-proliferative, cytotoxic, and induces the formation of intracellular 
vesicles in glioma cells. 
To investigate the effect of CBD treatment on cell line proliferation and 
cytotoxicity, we monitored cell viability via the IncuCyteTM in a selection of glioma cells 
including canine cell lines SDT3G and J3TBG and human cell lines U87MG and 
U373MG Uppsala (Figure 1). Two sources of CBD-dominant compounds were used, 
>99.9% pure CBD isolate, and cannabinoid diverse CBD extract (96% CBD). Cell 
proliferation decreased starkly following CBD isolate treatment (Figure 1a-b). The 
cytotoxicity of CBD against human and canine gliomas was also confirmed using the 
live/dead dye YOYO-1 (Figure 1c). This measure of cytotoxicity confirmed cell death at 
the three highest concentrations (7.5, 10, 20 µg/mL) for both sources of CBD. In all 
cases, glioma cells appeared to be marginally more sensitive to CBD isolate than CBD 
extract (Figure 1b-c); later experiments were conducted solely with the highly-purified 
CBD isolate.  Treatment with cytotoxic concentrations of CBD invariably induced the 




































Figure 1: CBD is antiproliferative and cytotoxic to glioma cell lines. a. U87MG, 
U373MG, J3Tbg and SDT3G Glioma cells were treated with CBD isolate (0 – 20 µg/mL) 
for 96 hours. Cell proliferation and dose response were measured via IncuCyteTM Red 
Object Count. Representative of n = 4 independent experiment. Individual points 
expressed as mean ± SEM, curve fit through a non-linear, variable slope regression b.  
IC50 values were determined for both CBD isolate and extract at 96 hours. 
Representative of n = 4 independent experiments c. U87MG, U373, J3TBG, and 
SDT3G Glioma cells were treated with CBD isolate or extract (0 – 20 µg/mL) for 96 
hours. Cytotoxicity was determined using the green fluorescent dye, YOYO-1. 
Representative of n = 4 independent experiments, expressed as mean ± SEM d. 
SDT3G glioma cells treated with 0 µg/mL CBD after 48 hours (I), SDT3G Glioma cells 
featuring formation of intracellular vesicles after 48 hours of treatment with 7.5 µg/ml 
CBD isolate (II). Red fluorescence represents nuclei of viable cells. Images were 
captured through a 10X Nikon objective. 
 
 
CBD induces apoptosis with involvement from the necroptotic kinase RIPK3. 
Next, we investigated the mode of cell death involved in CBD-mediated 
cytotoxicity. We investigated three primary means of cell death: apoptosis, necroptosis, 
and pyroptosis. To observe the contribution of apoptosis, glioma cell lines were treated 
with CBD (0-20 µg/mL) and zVAD-fmk (zVAD) (50 µM), a pan-caspase inhibitor for 96 
hours (Figure 2a). At cytotoxic CBD concentrations (7.5, 10, 20 µg/mL), zVAD prevented 
cell death and rescued cell viability across all cell lines.  To observe the contribution of 
necroptosis, glioma cell lines were treated with CBD and necrostatin-1 (100 µM), a 
RIPK1 inhibitor. At cytotoxic CBD concentrations, necrostatin-1 was unable to rescue 
CBD-induced cell death (Figure 2b). As part of our necroptosis investigation, we also 
inhibited RIPK3, a classically associated necroptotic kinase. Glioma cells were treated 
with CBD and GSK872 (1 µM), a RIPK3 inhibitor and putative inhibitor of necroptosis. At 
cytotoxic CBD concentrations, GSK872 rescued cells from CBD-induced cell death, but 
not to the same degree as zVAD, (Figure 2c) and prevented the formation of CBD-
mediated intracellular vesicles (supplementary figure). Finally, we investigated the 
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contribution of caspase-1 mediated pyroptosis as a mode of CBD-mediated cytotoxicity. 
U87MG and J3TBG Glioma cells were treated with CBD and VX-765 (Belnacasan, 50 
µM), a caspase-1 inhibitor. VX-765 was unable to rescue CBD-induced cell death in 
either cell line (supplementary).  
To characterize the timeline of CBD-mediated cytotoxicity, glioma cell lines were 
treated with CBD (0-20 µg/mL) for 96 hours. In an effort to rescue cells from CBD-
mediated cytotoxicity, sub-groups had the CBD-supplemented media replaced with 
fresh CBD-free media at 24 and 48 hours.  Across all cell lines, media replacement at 
24 hours was able to moderately rescue cell viability, while the media replacement at 48 
hours appeared similar to the no replacement control. Our data suggest that a 





























































Figure 2: CBD induces apoptosis with contribution from the protein kinase RIPK3. 
a. U87MG, U373MG, J3TBG, and SDT3G glioma cells were treated with CBD isolate (0 
- 20 µg/mL) and zVAD (50 µM) concurrently for 96 hours and cytotoxicity determined 
using the green fluorescent dye, YOYO-1. Representative of n = 3 independent 
experiments, expressed as mean ± SEM. *P<.05 (Student’s t-test). b. Cytotoxicity of 
glioma cells treated with CBD isolate (0 - 20 µg/mL) and necrostatin-1 (100 µM) 
concurrently for 96 hours. Representative of n = 3 independent experiments, expressed 
as mean ± SEM. *P<.05 (Student’s t-test). c. Cytotoxicity of glioma cells treated with 
CBD isolate (0 - 20 µg/mL) and GSK ‘872 (1 µM) concurrently for 96 hours. 




CBD impairs mitochondrial activity at sub-cytotoxic concentrations. 
U87MG and U373MG Uppsala human glioma cells were treated with CBD for 96 
hours and cytotoxicity was measured using two methods: (Figure 3a) resazurin 
reduction (surrogate of cell viability measuring mitochondrial function); and (Figure 3b) 
cell proliferation using red fluorescence on the IncuCyteTM. Treatment with CBD 
drastically impairs mitochondrial-based resazurin reduction, suggesting sensitivity at 
much lower concentrations of CBD than that determined by IncuCyteTM. Thus, CBD 
impairs mitochondrial activity at sub-cytotoxic concentrations without altering cell 
proliferation or death. This finding was confirmed via Seahorse XFe24 analysis of 
mitochondrial OCR (Figure 3c) and ECAR (supplementary) post-CBD treatment.  In all 
glioma cell lines, we observed a decrease in oxygen consumption reflecting inhibition of 
mitochondrial respiration that occurs long before detectable cytotoxicity. Treatment with 
CBD altered cellular ATP production at both sub-cytotoxic and lethal concentrations in a 
dose-dependent and time-sensitive manner. In all glioma cell lines, a decrease in ATP 
production after treatment with lethal and sub-cytotoxic concentrations of CBD was 

































Figure 3: CBD perturbs mitochondrial activity at lethal and non-lethal 
concentrations. a. Glioma cell lines U87MG and U373MG Uppsala were treated with 
CBD isolate (0 - 20 ug/mL) for 96 hours. Cell viability was determined via resazurin-
based metabolic assay. Data (arbitrary fluorescence units) were normalized to the 
vehicle treated control. Representative of n = 3 independent experiments, expressed as 
mean ± SEM. b. Glioma cell lines U87MG and U373MG Uppsala were treated with CBD 
isolate (0 - 20 µg/mL) for 96 hours. Cell proliferation was measured via IncuCyteTM Red 
Object Count. Representative of n = 3 independent experiments, expressed as mean ± 
SEM.  c. Glioma cells were measured for baseline oxygen consumption for 30 minutes, 
then treated with CBD at lethal (10 μg/mL) and non-lethal (2.5 μg/mL) concentrations. 
OCR was monitored for 500 minutes using the SeaHorse XF24. Representative of n = 1 
independent experiment that demonstrates trends observed across independently 
repeated experiments d. U87MG, U373, J3Tbg and SDT3G Glioma cells were treated 
with CBD isolate (2.5, 10 µg/mL) for 12, 24 and 48 hours. Cellular ATP production was 
determined via ATP luminescence kit. Data (fluorescence) were interpolated via 
standard curve, corrected for proliferation (Red Object Count via IncucyteTM) and 




Treatment with a lethal CBD concentration produces ultrastructural changes in 
the mitochondria. 
SDT3G and U373MG cells were stained with MitoTracker Deep Red FM and 
visualized by live cell imaging to investigate morphological changes related to CBD 
treatment. The untreated cell lines displayed a fibrillar mitochondrial network distributed 
throughout the cell (Figure 4a). Each cell line was then treated with a cytotoxic (10 
g/mL) and non-cytotoxic (2.5 g/mL) dose of CBD and visualized at time points 
throughout the known cell-death decision time frame (supplementary figure). Within 2 
hours post-treatment, both SDT3G (Figure 4b) and U373MG (Figure 4c) cells showed 
dramatic alteration of mitochondrial morphology and disruption of the fibrillar network 
but only at the high CBD concentration. At this concentration the mitochondria were 
very large and circular. Images for SDT3G at 48 hours post-high dose CBD treatment 
could not be captured because no viable cells remained. This phenomenon was not 
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observed at the low CBD concentration where the baseline mitochondrial morphology 
and network were largely preserved throughout the 48-hour time frame. The spherical 
mitochondria seemingly correspond to the large vesicles observed by brightfield in the 



































































Figure 4: CBD causes morphological changes in mitochondria. a. Untreated 
SDT3G and U373 MG cells demonstrate a fibrillar mitochondrial network. Following 
treatment with CBD, both SDT3G (b) and U373 MG (c) cells show dramatic changes in 
mitochondrial morphology within two hours of 10 g/mL CBD treatment that is not 
observed at 2.5 g/mL CBD. Nuclei are represented by dark blue and mitochondria are 
represented by cyan pseudo colors. 
 
CBD-mediated cytotoxicity involves VDAC1 but not TRPV1. 
Cell Lines U87MG, U373MG Uppsala, SDT3G, and J3TBG were treated concurrently 
with CBD (0-20 µg/mL) and IRTX (1 µM), a known inhibitor of TRPV1 (Figure 4a). At 
cytotoxic CBD concentrations, inhibition of TRPV1 was unable to rescue cell viability. 
Cell lines were treated with CBD (0-20 µg/mL) and DIDS (50 µM), a known inhibitor of 
the VDAC1. At cytotoxic CBD concentrations, inhibition of VDAC1 rescued cell viability 







































Figure 5: CBD mediated cytotoxicity involves VDAC1 but not TRPV1. a. U87MG, 
U373MG, J3TBG and SDT3G Glioma cells were treated with CBD isolate (0 - 20 µg/mL) 
and IRTX (1 µM) concurrently for 96 hours and cytotoxicity determined using the green 
fluorescent dye, YOYO-1. Representative of n = 3 independent experiments, expressed 
as mean ± SEM. *P<.05 (Student’s t-test). b.  Cytotoxicity of glioma cells treated with 
CBD isolate (0 - 20 µg/mL) and DIDS (50 µM) concurrently for 96 hours. Representative 











































Recent studies with cannabinoids have begun to identify potential activities that 
may be exploited for anticancer therapy. A wide range of antineoplastic effects on an 
array of histogenetically diverse cancers, relatively safe therapeutic index, and growing 
popularity in medicine and society makes them ideal candidates for further research. 
CBD has consistently induced apoptotic cell death in vitro and in vivo for many types of 
neoplasia.26,27,28 While the exact mechanism of action underlying this cytotoxicity has 
not been fully elucidated, it has been hypothesized that mitochondrial dysfunction 
precipitated by altering VDAC1 channel activity is central to the observed 
antiproliferative, apoptotic, and other antineoplastic signaling pathways.29,30,31 
 In this present study, we demonstrate that highly purified CBD isolate reduced 
proliferation and induced caspase-mediated cell death, suggestive of apoptosis, in both 
canine glioma cell lines SDT3G and J3TBG as well as the human glioma cell lines 
U87MG and U373MG Uppsala. The commitment to CBD-induced apoptotic cell death 
involves a critical cell fate decision between 24 and 48 hours. Our data also 
demonstrate that RIPK3, a protein kinase classically associated with necroptosis,32 
plays an impactful role in CBD-mediated cytotoxicity and formation of intracellular 
vesicles, suggesting a non-canonical function of the kinase. RIPK3 has been implicated 
as a proapoptotic adaptor after the formation of the necrosome, particularly when the 
core necroptotic machinery component Mixed Lineage Kinase domain-like protein 
(MLKL) is absent.23,32,33 Interestingly, the domestic dog (Canis lupus familiaris) does not 
possess the MLKL gene,34 perhaps highlighting an even more central role for RIPK3 in 
determining CBD sensitivity in canine gliomas. In addition, RIPK3 has also been 
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implicated in the execution of mitochondrial-mediated apoptosis in cardiac myocytes 
during hypoxic insult via inhibition of the FUNDC1 pathway, and thereby inhibition of 
mitophagy, a selective degradation of damaged mitochondria.35 Future investigation of 
these potential phenomena may help to clarify the exact biophysical mechanisms 
behind CBD-mediated cytotoxicity in glioma cells.  
 The effects of the cannabinoid family are extremely diverse and their exact 
mechanisms tend to be incompletely characterized, particularly in the oncology arena. 
CBD’s interaction with the TRP receptor family has been an exciting line of research 
and has been implicated in many of CBD’s observed therapeutic effects.16, 36,37 The 
TRP family is a multigene, superfamily of ion channels that produce a range of 
physiological effects.38  In particular, the TRPV1 receptor, a calcium ion channel found 
to be localized to the IMM of the mitochondria in nonneuronal cells,46 appears to have 
diverse cellular effects after exposure to CBD, with variability dependent on cell type, 
physiologic state, and CBD dosage. 16, 36,37  TRPV1 activation induces cell death after 
treatment with the TRPV1 agonist, capsaicin, via a rapid increase in intracellular 
calcium.39 CBD-induced intramitochondrial calcium overload has been implicated in the 
formation of the fatal mitochondrial permeability transition pore (mPTP) and subsequent 
CBD-mediated cell death, independent of the CB1/CB2 receptors. 28,29,31 Here, we 
sought to investigate if TRPV1 channel-mediated increases in mitochondrial calcium 
flux after CBD treatment might explain our observations. Pharmacologic inhibition of the 
TRPV1 receptor with IRTX, however, did not produce any protective effects across cell 
lines, suggesting the TRPV1 receptor is not involved with CBD-mediated cell death in 
our model. The VDAC1-Mitochondrial Calcium Uniporter complex , an outer and inner 
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mitochondrial membrane mediator of calcium uptake from the cytosol, is being 
investigated in CBD mediated cell death.29  Research has demonstrated colocalization 
and direct interaction of CBD and VDAC1, heavily implicating this channel in observed 
cellular energy pathologies.29 Pharmacologic inhibition of VDAC1 with DIDS produced 
stark protective effects on cell viability, suggesting that VDAC1 is a major contributor to 
CBD-mediated cell death. While pharmacologic inhibition of VDAC1 produced results in 
support of our hypothesis, we cannot exclude other off-target effects of DIDS, such as 
caspase inhibition. 24 Ideally, future studies will investigate individual genetic knockout 
or knockdown of the TRPV1, MCU, and VDAC1 channels to clarify their role in CBD-
mediated pathogenesis. 
 Targeted dysregulation of mitochondrial bioenergetics has become a leading 
hypothesis for the observed CBD anticancer effects. 26, 28, 29, 31 In this present study we 
show a significant perturbation of mitochondrial OCR and ECAR soon after treatment 
with both lethal and non-lethal doses of CBD that appears to persist for almost 6 hours 
post-treatment. Previous studies have demonstrated CBD’s ability to alter mitochondrial 
membrane potential, 29,31 which is delicately tied to Complex I function. These findings 
are corroborated qualitatively by the dramatic ultrastructural changes in mitochondria 
seen as soon as 2 hours post-treatment with a lethal dose of CBD (10 g/mL). Across 
all cell lines, these observed ultrastructural changes at 2-hours post-lethal treatment 
support the significant drop of OCR observed via the Seahorse XFe24 at approximately 
150 minutes (120 minutes post treatment). We hypothesize, at lethal concentrations, 
CBD alters permeability of the VDAC1 channel to facilitate a rapid influx of calcium into 
the mitochondria which leads to a loss of mitochondrial function due to perturbation of 
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membrane potential, release of reactive oxygen species (ROS), and depletion of ATP. 
This dysfunction also results in the formation of the mPTP, mitochondrial swelling, and 
subsequent cell death. Previous studies have demonstrated a cellular-protective effect 
of cyclosporine A, a mPTP inhibitor,40 but not with FK-506, a calcineurin inhibitor.41 The 
respective mechanism of action of these two drugs suggests the involvement of the 
mPTP in CBD-mediated cell death.28 
 In previous CBD studies, utilization of the MTT, resazurin, or other related 
metabolic assays has been the standard for assessing cell viability and cytotoxicity 
analysis. 27,42,43,44 The stark disparity between our resazurin reduction fluorescence data 
and cell proliferation data suggest that mitochondrial Complex I function is compromised 
at doses of CBD that have little to no effect on cell viability. Therefore, cell viability 
assays dependent on mitochondrial respiration may over-estimate CBD-mediated 
cytotoxicity and our results discourage continued use of these assays for CBD related 
studies. This also raises the tantalizing possibility that CBD might have therapeutic 
effects at sub-cytotoxic doses that could prove synergistic with other standard 
interventions such as temozolomide, external beam radiation, and perhaps ascorbic 
acid. 
The grave prognosis and relatively ineffective currently available treatment 
strategies make further glioma therapeutic research crucial. The growing body of 
knowledge of the pharmacology, anticancer effects, and other therapeutically relevant 
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Supplementary Figure: a. SDT3G Glioma cells featuring formation of intracellular 
vesicles after 48 hours of treatment with 7.5 µg/ml CBD isolate (I), SDT3G Glioma cells 
featuring absence of intracellular vesicles after 48 hours of concurrent treatment with 
7.5 µg/ml CBD isolate and GSK ‘872 (1 µM) (II). b. Cytotoxicity of U87MG and J3TBG 
glioma cells treated with CBD isolate (0 - 20 µg/mL) and VX-765 (50 µM) concurrently 
for 96 hours. Representative of n = 2 independent experiments c. Relative growth of 
glioma cells (Control = 100%) treated with CBD isolate (0 - 20 µg/mL) for 96 hours, sub-
groups had the CBD-supplemented media replaced with fresh CBD-free media at 24 
and 48 hours. Representative of n = 1 independent experiments d. Glioma cells were 
measured for baseline extracellular acidification rate for 30 minutes, then treated with 
CBD at lethal (10 μg/mL) and non-lethal (2.5 μg/mL) concentrations. ECAR was 
monitored for 500 minutes using the SeaHorse XF24. Representative of n = 1 


































LIST OF ABBRIEVIATIONS 
 
 
CBD – Cannabidiol 
DIDS - 4,4’-Diisothiocyano-2,2’-stilbenedisulfonic acid 
OCR – Oxygen Consumption Rate 
ECAR – Extra Cellular Acidification Rate 
GPCR – G-coupled Protein Receptor 
TRPV1 – Transient Receptor Potential Cation Channel subfamily V 
mTOR – Mammalian Target of Rapamycin 
THC -Tetrahydrocannibinol 
PPAR – Peroxisome Proliferator-Activated Receptor 
CB1/2 – Cannabinoid Receptor ½ 
GABA – Gamma Aminobutryic Acid 
5-HT – 5 Hydroxytryptamine Receptor 
MRI – Magnetic Resonance Imaging 
 
